NCT06824363View on ClinicalTrials.gov

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2028

Conditions
Solid Tumor, AdultMalignant Solid TumorStomach AdenocarcinomaEsophageal Adenocarcinoma
Interventions
DRUG

Tremelimumab

single dose, 300mg IV, day 1

DRUG

Durvalumab

single dose, 1500 mg IV, day 1

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER